Title: HOUSE BILL 1131
Official Title: HOUSE BILL 1131
Number of Sections: 1
Source: versions - Third - Public Health - Buprenorphine - Training Grant Program and Workgroup
Media Type: application/pdf
Strikethrough Detection: 6 sections found

================================================================================

Section 1:
J1, F2 5lr2053
By: Delegates Vogel and Tomlinson
Introduced and read first time: February 5, 2025
Assigned to: Health and Government Operations
Committee Report: Favorable
House action: Adopted
Read second time: March 1, 2025
CHAPTER ______
1 AN ACT concerning
2 Public Health – Buprenorphine – Training Grant Program and Workgroup
3 FOR the purpose of establishing the Buprenorphine Training Grant Program to assist
4 counties with offsetting the cost of training paramedics to administer buprenorphine;
5 including the Program as an authorized use of funding from the Opioid Restitution
6 Fund; requiring the Maryland Office of Overdose Response to convene a workgroup
7 to study access to buprenorphine in the State; and generally relating to
8 buprenorphine.
9 BY adding to
10 Article – Health – General
11 Section 13–5501 and 13–5502 to be under the new subtitle “Subtitle 55.
12 Buprenorphine Training Grant Program”
13 Annotated Code of Maryland
14 (2023 Replacement Volume and 2024 Supplement)
15 BY repealing and reenacting, without amendments,
16 Article – State Finance and Procurement
17 Section 7–331(a) through (e)
18 Annotated Code of Maryland
19 (2021 Replacement Volume and 2024 Supplement)
20 BY repealing and reenacting, with amendments,
21 Article – State Finance and Procurement
22 Section 7–331(f)
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law.
Underlining indicates amendments to bill.
Strike out indicates matter stricken from the bill by amendment or deleted from the law by
amendment. *hb1131*
2 HOUSE BILL 1131
1 Annotated Code of Maryland
2 (2021 Replacement Volume and 2024 Supplement)
3 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
4 That the Laws of Maryland read as follows:
5 Article – Health – General
6 SUBTITLE 55. BUPRENORPHINE TRAINING GRANT PROGRAM.
7 13–5501.
8 (A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS
9 INDICATED.
10 (B) “PARAMEDIC” HAS THE MEANING STATED IN § 13–516 OF THE
11 EDUCATION ARTICLE.
12 (C) “PROGRAM” MEANS THE BUPRENORPHINE TRAINING GRANT
13 PROGRAM.
14 13–5502.
15 (A) (1) THERE IS A BUPRENORPHINE TRAINING GRANT PROGRAM IN
16 THE DEPARTMENT.
17 (2) THE PURPOSE OF THE PROGRAM IS TO ASSIST A COUNTY WITH
18 OFFSETTING THE COST OF TRAINING PARAMEDICS TO ADMINISTER
19 BUPRENORPHINE.
20 (B) A COUNTY MAY APPLY TO THE DEPARTMENT FOR A GRANT FROM THE
21 PROGRAM.
22 (C) A COUNTY MAY USE A GRANT AWARDED UNDER THE PROGRAM ONLY
23 FOR TRAINING PARAMEDICS TO ADMINISTER BUPRENORPHINE.
24 (D) THE GOVERNOR SHALL INCLUDE IN THE ANNUAL BUDGET BILL AN
25 APPROPRIATION OF AT LEAST $50,000 FROM THE OPIOID RESTITUTION FUND FOR
26 THE PROGRAM.
27 Article – State Finance and Procurement
28 7–331.
29 (a) In this section, “Fund” means the Opioid Restitution Fund.
HOUSE BILL 1131 3
1 (b) There is an Opioid Restitution Fund.
2 (c) The purpose of the Fund is to retain the amount of settlement revenues
3 deposited to the Fund in accordance with subsection (e)(1) of this section.
4 (d) (1) The Fund is a special, nonlapsing fund that is not subject to § 7–302 of
5 this subtitle.
6 (2) The State Treasurer shall hold the Fund separately, and the
7 Comptroller shall account for the Fund.
8 (e) The Fund consists of:
9 (1) all revenues received by the State from any source resulting, directly or
10 indirectly, from any judgment against, or settlement with, opioid manufacturers, opioid
11 research associations, or any other person in the opioid industry relating to any claims
12 made or prosecuted by the State to recover damages for violations of State law; and
13 (2) the interest earnings of the Fund.
14 (f) The Fund may be used only to provide funds for:
15 (1) programs, services, supports, and resources for evidence–based
16 substance use disorder prevention, treatment, recovery, or harm reduction that have the
17 purpose of:
18 (i) improving access to medications proven to prevent or reverse an
19 overdose, including by supporting the initiative to co–locate naloxone with automated
20 external defibrillators placed in public buildings under § 13–518 of the Education Article;
21 (ii) supporting peer support specialists and screening, brief
22 intervention, and referral to treatment services for hospitals, correctional facilities, and
23 other high–risk populations;
24 (iii) increasing access to medications that support recovery from
25 substance use disorders;
26 (iv) expanding the Heroin Coordinator Program, including for
27 administrative expenses;
28 (v) expanding access to crisis beds and residential treatment
29 services for adults and minors;
30 (vi) expanding and establishing safe stations, mobile crisis response
31 systems, and crisis stabilization centers;
4 HOUSE BILL 1131
1 (vii) supporting the behavioral health crisis hotline;
2 (viii) organizing primary and secondary school education campaigns
3 to prevent opioid use, including for administrative expenses;
4 (ix) enforcing the laws regarding opioid prescriptions and sales,
5 including for administrative expenses;
6 (x) research regarding and training for substance use treatment and
7 overdose prevention, including for administrative expenses; and
8 (xi) supporting and expanding other evidence–based interventions
9 for overdose prevention and substance use treatment;
10 (2) supporting community–based nonprofit recovery organizations that
11 provide nonclinical substance use recovery support services in the State;
12 (3) evidence–informed substance use disorder prevention, treatment
13 recovery, or harm reduction pilot programs or demonstration studies that are not
14 evidence–based if the Opioid Restitution Fund Advisory Council, established under §
15 7.5–902 of the Health – General Article:
16 (i) determines that emerging evidence supports the distribution of
17 money for the pilot program or that there is a reasonable basis for funding the
18 demonstration study with the expectation of creating an evidence–based program; and
19 (ii) approves the use of money for the pilot program or demonstration
20 study; [and]
21 (4) evaluations of the effectiveness and outcomes reporting for substance
22 use disorder abatement infrastructure, programs, services, supports, and resources for
23 which money from the Fund was used, including evaluations of the impact on access to
24 harm reduction services or treatment for substance use disorders and the reduction in
25 drug–related mortality; AND
26 (5) THE BUPRENORPHINE TRAINING GRANT PROGRAM
27 ESTABLISHED UNDER § 13–5502 OF THE HEALTH – GENERAL ARTICLE.
28 SECTION 2. AND BE IT FURTHER ENACTED, That:
29 (a) The Maryland Office of Overdose Response shall convene a workgroup to
30 study access to buprenorphine in the State.
31 (b) The workgroup shall include:
32 (1) one member of the Senate of Maryland, appointed by the President of
33 the Senate;
HOUSE BILL 1131 5
1 (2) one member of the House of Delegates, appointed by the Speaker of the
2 House; and
3 (3) representatives of:
4 (i) the Maryland Institute of Emergency Medical Services Systems;
5 (ii) the Behavioral Health Administration;
6 (iii) hospitals;
7 (iv) local behavioral health agencies; and
8 (v) the Maryland Association of Counties.
9 (c) The workgroup shall examine:
10 (1) how buprenorphine services are offered in the State;
11 (2) the capacity of providers to provide buprenorphine;
12 (3) any geographic areas where significant gaps in buprenorphine services
13 may exist;
14 (4) the feasibility of financial support for a long–term expansion of
15 buprenorphine services;
16 (5) a plan for ongoing data collection for the purpose of the monitoring and
17 improvement of buprenorphine services;
18 (6) how to effectively grow a hub–and–spoke model to ensure access to
19 buprenorphine in the State; and
20 (7) any other strategies that would improve buprenorphine services in the
21 State.
22 (d) On or before December 31, 2025, the Maryland Office of Overdose Response
23 shall submit a report on the findings and recommendations of the workgroup, including the
24 need for any statutory changes, to the Governor and, in accordance with § 2–1257 of the
25 State Government Article, the Senate Finance Committee and the House Health and
26 Government Operations Committee.
27 SECTION 3. AND BE IT FURTHER ENACTED, That Section 1 of this Act shall take
28 effect October 1, 2025. Section 1 of this Act shall remain in effect for a period of 5 years and,
29 at the end of September 30, 2030, Section 1 of this Act, with no further action required by
30 the General Assembly, shall be abrogated and of no further force and effect.
6 HOUSE BILL 1131
1 SECTION 4. AND BE IT FURTHER ENACTED, That, except as provided in Section
2 3 of this Act, this Act shall take effect July 1, 2025. Section 2 of this Act shall remain
3 effective for a period of 1 year and, at the end of June 30, 2026, Section 2 of this Act, with
4 no further action required by the General Assembly, shall be abrogated and of no further
5 force and effect.
Approved:
________________________________________________________________________________
Governor.
________________________________________________________________________________
Speaker of the House of Delegates.
________________________________________________________________________________
President of the Senate.
[DELETED: :CA      5     A P F t p o e t B T G P t a c i F t s a t b i t S a g r t b B  A S 1 a 1 t b u t n s “ 5 B  A  ( B  A  S  A  ( B  A  S]
[DELETED:  H   A  (  S T A5.BTGP.  U R R R ) N T S T F W H T M() “P”§1AC H T M S I   O TA. R() “P”BTRM M T U R R.() ( TBTGH I A U R R R I E. ( T R T C O T P T A() A  E () A  RE() TH O S I I T A B B A   P E U0OR RM. A 7  ( I]
[DELETED: H 3  ( T  ( T p o t F i t r t a o s r d  ( ( T t   ( T S T s h t F s a t C  ( T   ( a i r m   ( t  ( T   ( p s s a r f e s p    ( i o i b s t i t c n w a e    ( s p s s a s b i o    ( i a t m t s r f s    ( e t H C P i f a    ( e a t c b a r t s    ( e s]
[DELETED:  H     ( s    ( o t    ( e t l r o p a s i    ( r o    ( s a e o e i f   ( s c n r o t p   ( e s u d p t r o h r p p o d s t a n e i t O R F A C e u § 7    ( d m f t p p o t t i a r b f f t d    ( a s a]   ( e u d a i p s s a r f w h s dy ( BTG U R R R    E  E R12H–GA   S  ( T M O o O R s c a w t s  ( T   ( o t]
[DELETED: H 5   ( o H   ( r    ( t    ( t    ( h    ( l    ( t  ( T   ( h   ( t   ( a m   ( t f o f s f a l e o b   ( a i   ( h t e g a h m t e a t b   ( a S  ( O s n S G A t S F C a t H H a G  S e a t]
[DELETED:  H   S 3 e n f          G               ]


================================================================================

Raw Text:
HOUSE BILL 1131
J1, F2 5lr2053
By: Delegates Vogel and Tomlinson
Introduced and read first time: February 5, 2025
Assigned to: Health and Government Operations
Committee Report: Favorable
House action: Adopted
Read second time: March 1, 2025
CHAPTER ______
1 AN ACT concerning
2 Public Health – Buprenorphine – Training Grant Program and Workgroup
3 FOR the purpose of establishing the Buprenorphine Training Grant Program to assist
4 counties with offsetting the cost of training paramedics to administer buprenorphine;
5 including the Program as an authorized use of funding from the Opioid Restitution
6 Fund; requiring the Maryland Office of Overdose Response to convene a workgroup
7 to study access to buprenorphine in the State; and generally relating to
8 buprenorphine.
9 BY adding to
10 Article – Health – General
11 Section 13–5501 and 13–5502 to be under the new subtitle “Subtitle 55.
12 Buprenorphine Training Grant Program”
13 Annotated Code of Maryland
14 (2023 Replacement Volume and 2024 Supplement)
15 BY repealing and reenacting, without amendments,
16 Article – State Finance and Procurement
17 Section 7–331(a) through (e)
18 Annotated Code of Maryland
19 (2021 Replacement Volume and 2024 Supplement)
20 BY repealing and reenacting, with amendments,
21 Article – State Finance and Procurement
22 Section 7–331(f)
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law.
Underlining indicates amendments to bill.
Strike out indicates matter stricken from the bill by amendment or deleted from the law by
amendment. *hb1131*

2 HOUSE BILL 1131
1 Annotated Code of Maryland
2 (2021 Replacement Volume and 2024 Supplement)
3 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
4 That the Laws of Maryland read as follows:
5 Article – Health – General
6 SUBTITLE 55. BUPRENORPHINE TRAINING GRANT PROGRAM.
7 13–5501.
8 (A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS
9 INDICATED.
10 (B) “PARAMEDIC” HAS THE MEANING STATED IN § 13–516 OF THE
11 EDUCATION ARTICLE.
12 (C) “PROGRAM” MEANS THE BUPRENORPHINE TRAINING GRANT
13 PROGRAM.
14 13–5502.
15 (A) (1) THERE IS A BUPRENORPHINE TRAINING GRANT PROGRAM IN
16 THE DEPARTMENT.
17 (2) THE PURPOSE OF THE PROGRAM IS TO ASSIST A COUNTY WITH
18 OFFSETTING THE COST OF TRAINING PARAMEDICS TO ADMINISTER
19 BUPRENORPHINE.
20 (B) A COUNTY MAY APPLY TO THE DEPARTMENT FOR A GRANT FROM THE
21 PROGRAM.
22 (C) A COUNTY MAY USE A GRANT AWARDED UNDER THE PROGRAM ONLY
23 FOR TRAINING PARAMEDICS TO ADMINISTER BUPRENORPHINE.
24 (D) THE GOVERNOR SHALL INCLUDE IN THE ANNUAL BUDGET BILL AN
25 APPROPRIATION OF AT LEAST $50,000 FROM THE OPIOID RESTITUTION FUND FOR
26 THE PROGRAM.
27 Article – State Finance and Procurement
28 7–331.
29 (a) In this section, “Fund” means the Opioid Restitution Fund.

HOUSE BILL 1131 3
1 (b) There is an Opioid Restitution Fund.
2 (c) The purpose of the Fund is to retain the amount of settlement revenues
3 deposited to the Fund in accordance with subsection (e)(1) of this section.
4 (d) (1) The Fund is a special, nonlapsing fund that is not subject to § 7–302 of
5 this subtitle.
6 (2) The State Treasurer shall hold the Fund separately, and the
7 Comptroller shall account for the Fund.
8 (e) The Fund consists of:
9 (1) all revenues received by the State from any source resulting, directly or
10 indirectly, from any judgment against, or settlement with, opioid manufacturers, opioid
11 research associations, or any other person in the opioid industry relating to any claims
12 made or prosecuted by the State to recover damages for violations of State law; and
13 (2) the interest earnings of the Fund.
14 (f) The Fund may be used only to provide funds for:
15 (1) programs, services, supports, and resources for evidence–based
16 substance use disorder prevention, treatment, recovery, or harm reduction that have the
17 purpose of:
18 (i) improving access to medications proven to prevent or reverse an
19 overdose, including by supporting the initiative to co–locate naloxone with automated
20 external defibrillators placed in public buildings under § 13–518 of the Education Article;
21 (ii) supporting peer support specialists and screening, brief
22 intervention, and referral to treatment services for hospitals, correctional facilities, and
23 other high–risk populations;
24 (iii) increasing access to medications that support recovery from
25 substance use disorders;
26 (iv) expanding the Heroin Coordinator Program, including for
27 administrative expenses;
28 (v) expanding access to crisis beds and residential treatment
29 services for adults and minors;
30 (vi) expanding and establishing safe stations, mobile crisis response
31 systems, and crisis stabilization centers;

4 HOUSE BILL 1131
1 (vii) supporting the behavioral health crisis hotline;
2 (viii) organizing primary and secondary school education campaigns
3 to prevent opioid use, including for administrative expenses;
4 (ix) enforcing the laws regarding opioid prescriptions and sales,
5 including for administrative expenses;
6 (x) research regarding and training for substance use treatment and
7 overdose prevention, including for administrative expenses; and
8 (xi) supporting and expanding other evidence–based interventions
9 for overdose prevention and substance use treatment;
10 (2) supporting community–based nonprofit recovery organizations that
11 provide nonclinical substance use recovery support services in the State;
12 (3) evidence–informed substance use disorder prevention, treatment
13 recovery, or harm reduction pilot programs or demonstration studies that are not
14 evidence–based if the Opioid Restitution Fund Advisory Council, established under §
15 7.5–902 of the Health – General Article:
16 (i) determines that emerging evidence supports the distribution of
17 money for the pilot program or that there is a reasonable basis for funding the
18 demonstration study with the expectation of creating an evidence–based program; and
19 (ii) approves the use of money for the pilot program or demonstration
20 study; [and]
21 (4) evaluations of the effectiveness and outcomes reporting for substance
22 use disorder abatement infrastructure, programs, services, supports, and resources for
23 which money from the Fund was used, including evaluations of the impact on access to
24 harm reduction services or treatment for substance use disorders and the reduction in
25 drug–related mortality; AND
26 (5) THE BUPRENORPHINE TRAINING GRANT PROGRAM
27 ESTABLISHED UNDER § 13–5502 OF THE HEALTH – GENERAL ARTICLE.
28 SECTION 2. AND BE IT FURTHER ENACTED, That:
29 (a) The Maryland Office of Overdose Response shall convene a workgroup to
30 study access to buprenorphine in the State.
31 (b) The workgroup shall include:
32 (1) one member of the Senate of Maryland, appointed by the President of
33 the Senate;

HOUSE BILL 1131 5
1 (2) one member of the House of Delegates, appointed by the Speaker of the
2 House; and
3 (3) representatives of:
4 (i) the Maryland Institute of Emergency Medical Services Systems;
5 (ii) the Behavioral Health Administration;
6 (iii) hospitals;
7 (iv) local behavioral health agencies; and
8 (v) the Maryland Association of Counties.
9 (c) The workgroup shall examine:
10 (1) how buprenorphine services are offered in the State;
11 (2) the capacity of providers to provide buprenorphine;
12 (3) any geographic areas where significant gaps in buprenorphine services
13 may exist;
14 (4) the feasibility of financial support for a long–term expansion of
15 buprenorphine services;
16 (5) a plan for ongoing data collection for the purpose of the monitoring and
17 improvement of buprenorphine services;
18 (6) how to effectively grow a hub–and–spoke model to ensure access to
19 buprenorphine in the State; and
20 (7) any other strategies that would improve buprenorphine services in the
21 State.
22 (d) On or before December 31, 2025, the Maryland Office of Overdose Response
23 shall submit a report on the findings and recommendations of the workgroup, including the
24 need for any statutory changes, to the Governor and, in accordance with § 2–1257 of the
25 State Government Article, the Senate Finance Committee and the House Health and
26 Government Operations Committee.
27 SECTION 3. AND BE IT FURTHER ENACTED, That Section 1 of this Act shall take
28 effect October 1, 2025. Section 1 of this Act shall remain in effect for a period of 5 years and,
29 at the end of September 30, 2030, Section 1 of this Act, with no further action required by
30 the General Assembly, shall be abrogated and of no further force and effect.

6 HOUSE BILL 1131
1 SECTION 4. AND BE IT FURTHER ENACTED, That, except as provided in Section
2 3 of this Act, this Act shall take effect July 1, 2025. Section 2 of this Act shall remain
3 effective for a period of 1 year and, at the end of June 30, 2026, Section 2 of this Act, with
4 no further action required by the General Assembly, shall be abrogated and of no further
5 force and effect.
Approved:
________________________________________________________________________________
Governor.
________________________________________________________________________________
Speaker of the House of Delegates.
________________________________________________________________________________
President of the Senate.

[DELETED: :CA      5     A P F t p o e t B T G P t a c i F t s a t b i t S a g r t b B  A S 1 a 1 t b u t n s “ 5 B  A  ( B  A  S  A  ( B  A  S]
[DELETED:  H   A  (  S T A5.BTGP.  U R R R ) N T S T F W H T M() “P”§1AC H T M S I   O TA. R() “P”BTRM M T U R R.() ( TBTGH I A U R R R I E. ( T R T C O T P T A() A  E () A  RE() TH O S I I T A B B A   P E U0OR RM. A 7  ( I]
[DELETED: H 3  ( T  ( T p o t F i t r t a o s r d  ( ( T t   ( T S T s h t F s a t C  ( T   ( a i r m   ( t  ( T   ( p s s a r f e s p    ( i o i b s t i t c n w a e    ( s p s s a s b i o    ( i a t m t s r f s    ( e t H C P i f a    ( e a t c b a r t s    ( e s]
[DELETED:  H     ( s    ( o t    ( e t l r o p a s i    ( r o    ( s a e o e i f   ( s c n r o t p   ( e s u d p t r o h r p p o d s t a n e i t O R F A C e u § 7    ( d m f t p p o t t i a r b f f t d    ( a s a]   ( e u d a i p s s a r f w h s dy ( BTG U R R R    E  E R12H–GA   S  ( T M O o O R s c a w t s  ( T   ( o t]
[DELETED: H 5   ( o H   ( r    ( t    ( t    ( h    ( l    ( t  ( T   ( h   ( t   ( a m   ( t f o f s f a l e o b   ( a i   ( h t e g a h m t e a t b   ( a S  ( O s n S G A t S F C a t H H a G  S e a t]
[DELETED:  H   S 3 e n f          G               ]